AstraZeneca Signs Co-promotion Deal with Daiichi Sankyo for Denosumab

Under the agreement, AstraZeneca and Daiichi Sankyo will co-promote denosumab after it is approved for use in Japan.

Biopharmaceutical company AstraZeneca has signed a co-promotion agreement in Japan with Daiichi Sankyo for denosumab for the treatment of bone disorders stemming from bone metastasis. AstraZeneca and Daiichi Sankyo will co-promote denosumab after it is approved for use in Japan.

Bone metastasis is one of the most frequent causes of pain for cancer patients which can cause bone fractures and reduces ability to maintain normal quality of life including day-to-day activities. Denosumab, with its novel mode of action and targeted delivery via a monthly subcutaneous injection, represents a new treatment option in Japan for the management of bone metastasis across a broad range of cancer types.

In Japan, Daiichi Sankyo acqui